2158 Comparative Outcomes of GLP-1 Receptor Agonists versus Glyburide in ICH Patients With Type 2 Diabetes: A Real-World Analysis Using the TriNetX Live Database

View at publisher Summarise with VIRAT
Authors: FNU Ruchika, Melanie Alfonzo Horowitz, Harshal Shah, Eli Yazigi, L. Fernando Gonzalez
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardiovascular and neuroprotective benefits, raising interest in their potential to improve outcomes after intracerebral hemorrhage (ICH). METHODS: Using the TriNetX Analytics Network on May 3, 2025, we identified adults (>18 years) diagnosed with both type 2 diabetes and ICH who were prescribed either GLP-1RAs or glyburide. Patient demographics, baseline characteristics, comorbidities, and clinical outcomes were evaluated. 1:1 Propensity score matching on 23 characteristics yielded two well-balanced cohorts with 4,777 patients each. RESULTS: The GLP-1RA cohort consisted of 9,776 patients with a mean age of 64.0 ± 12.5 years and 44.9% females, while the glyburide cohort included 4,840 patients with a mean age of 70.9 ± 12.0 years and 40.6% females. The GLP-1 cohort had a higher proportion of patients with obesity (51.8% vs. 26.1%), hyperlipidemia (72.7% vs. 65.6%), and tobacco use (7.3% vs. 3.5%) compared to the glyburide cohort (p-value < 0.0001). The prevalence of hypertension was similar between groups (88.7% vs. 89.4%, p = 0.18). Prior to matching, GLP-1 use was associated with lower hazard of seizures (HR 0.801, 0.693–0.926), re-bleeding (HR 0.751, 0.631–0.893), and all-cause mortality (HR 0.435, 0.404–0.468). After matching, GLP-1 use remained protective against seizures (HR 0.677, 0.539–0.851), hydrocephalus (HR 0.701, 0.526-0.934) and all-cause mortality (HR 0.485, 0.440–0.536). CONCLUSIONS: GLP-1 receptor agonist use in patients with ICH and type 2 diabetes was associated with significantly lower risks of seizures, hydrocephalus and all-cause mortality 5 years after ICH. These findings warrant further investigation into the clinical and mechanistic role of GLP-1RA as a neuroprotective agent post ICH.

Fields of Study & Subjects

Intracerebral and Subarachnoid Hemorrhage Research Diabetes Treatment and Management Acute Ischemic Stroke Management

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
289–289
Publication date
26 March 2026
Language
EN